Effects of Different Anti-Rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar.

Trial Profile

Effects of Different Anti-Rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Antirheumatics
  • Indications Pneumococcal infections; Rheumatic disorders; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms PVA
  • Most Recent Events

    • 14 Sep 2017 Planned End Date changed from 1 Dec 2013 to 1 Dec 2018.
    • 14 Sep 2017 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2018.
    • 23 Sep 2015 Status changed from recruiting to active, no longer recruiting as per info from results published in journal "Arthritis Research and Therapy" 505 patients have been enrolled which is > than planned accrual according to CT.gov [Last updated: November 6, 2013] which is showing status "study is enrolling participants by invitation only".As CT.gov is not recently updated and end date is passed it seems that enrollment has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top